Orthopaedic & Rheumatologic Institute Outcomes

The 2018 American College of Rheumatology/National Psoriasis Foundation guideline¹ served as a tool for health care providers and patients in the selection of appropriate therapy in common clinical scenarios. Discussion of the role for an oral small molecule (methotrexate, sulfasalazine, cyclosporine, leflunomide, apremilast) or a biologic agent (anti-tumor necrosis factor inhibitors, CTLA4-Ig, anti-lL-17 and anti-lL-23 inhibitors) in the treatment of psoriatic arthritis is recommended. More than 92.2% of psoriatic arthritis patients who were seen in the department at least 2 times during the years 2018–2022 were treated with an oral small molecule or a biologic agent. Reasons for not prescribing these therapies for the small percentage of patients not receiving them included disease remission, refusal of treatment, and contraindications to this type of therapy. In any given year, between 90.0% and 94.3% of patients were on an oral small molecule or biologic agent.

¹Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019 Jan;71(1):5-32